Bayer Company Newshttp://www.research.bayer.comTue, 22 May 2012 15:24:01 GMTBayer AG, Leverkusen, GermanyBayer Company Newshttp://www.research.bayer.com/img/Bayer_Logo_120.pngBayer Company Newshttp://www.research.bayer.com12042enPhase III MISSION Trial of Nexavar® in Patients with Non-Small Cell Lung Cancer Did Not Meet Primary Endpoint of Improving Overall Survivalhttp://www.research.bayer.com/en/News-Detail.aspx?newsid=19701Tue, 22 May 2012 06:30:00 GMTBayer to Present Data on Late-Stage Development Oncology Compounds at ASCO 2012http://www.research.bayer.com/en/News-Detail.aspx?newsid=19699Wed, 16 May 2012 12:00:00 GMTFirst data from Phase III trial for regorafenib in gastrointestinal tumors (GIST) presented as Late-Breaking Abstract in Oral Abstract Session / Updated survival results from Phase III trial for Alpharadin (radium-223 chloride) in castration-resistant prostate cancer (CRPC) presented as Late-Breaking Abstract in Oral Abstract SessionBayer expands targeted cancer therapy collaboration with Amgenhttp://www.research.bayer.com/en/News-Detail.aspx?newsid=19680Tue, 24 Apr 2012 06:30:00 GMTBayer to Present New Data on Oncology Pipelinehttp://www.research.bayer.com/en/News-Detail.aspx?newsid=19674Wed, 28 Mar 2012 11:00:00 GMTNew Preclinical Data Evaluating Innovative Compounds will be presented / Growing Research and Development PortfolioBayer HealthCare and Beijing’s Tsinghua University extend innovative drug discovery partnershiphttp://www.research.bayer.com/en/News-Detail.aspx?newsid=19672Tue, 27 Mar 2012 08:00:00 GMT